Evidence map›Paper›PMID 33515210›Full record

ReviewImmunologic research2021

Effect of interleukin-6, -17, -21, -22, and -23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis.

Izabela Woś, Jacek Tabarkiewicz

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunologic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Izabela WośLaboratory for Translational Research in Medicine, Centre for Innovative Research in Medical and Natural Sciences, College for Medical Sciences of University of Rzeszow, ul. Warzywna 1a, 35-310, Rzeszow, Poland. izabela-wos@wp.pl.ORCID http://orcid.org/0000-0003-4888-8785
Jacek TabarkiewiczLaboratory for Translational Research in Medicine, Centre for Innovative Research in Medical and Natural Sciences, College for Medical Sciences of University of Rzeszow, ul. Warzywna 1a, 35-310, Rzeszow, Poland.ORCID https://orcid.org/0000-0002-1264-2882
University of Rzeszów · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatic diseases are complex autoimmune diseases which include among others rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and psoriatic arthritis (PsA). These diseases are characterized by prolonged and increased secretion of inflammatory factors, eventually leading to inflammation. This is often accompanied by persistent pain and stiffness in the joint and finally bone destruction and osteoporosis. These diseases can occur at any age, regardless of gender or origin. Autoimmune arthritis is admittedly associated with long-term treatment, and discontinuation of medication is associated with unavoidable relapse. Therefore, it is important to detect the disease at an early stage and apply appropriate preventative measures. During inflammation, pro-inflammatory factors such as interleukins (IL)-6, -17, -21, -22, and -23 are secreted, while anti-inflammatory factors including IL-10 are downregulated. Research conducted over the past several years has focused on inhibiting inflammatory pathways and activating anti-inflammatory factors to improve the quality of life of people with rheumatic diseases. The aim of this paper is to review current knowledge on stimulatory and inhibitory pathways involving the signal transducer and activator of transcription 3 (STAT3). STAT3 has been shown to be one of the crucial factors involved in inflammation and is directly linked with other pro-inflammatory factors and thus is a target of current research on rheumatoid diseases.

Indexed as

AnimalsAnti-Inflammatory AgentsArthritisAutoimmune DiseasesHumansInterleukin-17Interleukin-21Interleukin-22Interleukin-23Interleukin-6InterleukinsMolecular Targeted TherapySignal TransductionSTAT3 Transcription FactorAnti-Inflammatory AgentsInterleukin-17Interleukin-21Interleukin-22Interleukin-23Interleukin-6InterleukinsSTAT3 Transcription FactorAnti-inflamatory drugsAutoimmune arthritisInterleukinSTAT3

Identifiers

PMID33515210
PMCPMC7921069
OpenAlexW3121177893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.